Kazia Therapeutics Regains Full Nasdaq Listing Compliance
Rhea-AI Summary
Kazia Therapeutics (NASDAQ: KZIA) regained full compliance with all Nasdaq listing standards on Dec 18, 2025 after Nasdaq confirmed the company meets Listing Rule 5550(b)(1) (the $2.5 million minimum stockholders' equity alternative to MVLS).
The restoration follows a $50 million private placement led by healthcare institutional investors that the company says materially strengthened its balance sheet; the previously scheduled Nasdaq hearing was cancelled as moot and Kazia's ADS will continue trading on The Nasdaq Capital Market.
Positive
- $50 million private placement completed
- Regained compliance with Nasdaq Listing Rule 5550(b)(1)
- Previously scheduled Nasdaq hearing cancelled as moot
- American Depositary Shares continue trading on Nasdaq Capital Market
Negative
- Company required a financing to restore Nasdaq compliance
- Prior noncompliance triggered a scheduled Nasdaq hearing
News Market Reaction – KZIA
In the Dec 22 session, KZIA declined 8.00%, reflecting a notable negative market reaction. Argus tracked a peak move of +2.6% during that session. Argus tracked a trough of -34.9% from its starting point during tracking. Our momentum scanner triggered 28 alerts that day, indicating elevated trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Dec 10 | Breast cancer data | Positive | -17.8% | Translational and early clinical paxalisib data in HER2+ and TNBC. |
| Dec 02 | Private placement | Positive | +9.9% | Announced $50.0M PIPE financing at $5.00 per ADS-equivalent. |
| Nov 18 | Breast cancer iCR | Positive | -5.3% | Reported initial immune-complete response in metastatic TNBC patient. |
| Oct 27 | GBM survival update | Positive | +4.6% | Planned FDA Type C meeting on GBM OS data and pathway. |
| Oct 07 | Licensing deal | Positive | +5.3% | Exclusive in-licensing of first-in-class PD-L1 protein degrader program. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news has produced mixed reactions: several positive clinical and strategic updates saw gains, but some strong breast cancer data triggered notable selloffs.
Over the last few months, Kazia has focused on advancing its oncology pipeline and stabilizing its listing status. On Oct 7, it in-licensed a first-in-class PD-L1 degrader program. On Oct 27, it highlighted encouraging GBM survival data and planned an FDA Type C meeting. Subsequent breast cancer data on Nov 18 and Dec 10 showcased paxalisib’s activity but drew mixed price reactions. A $50.0 million private placement on Dec 2 strengthened liquidity and underpins today’s Nasdaq compliance restoration.
Key Terms
stockholders' equity financial
market value of listed securities financial
private placement financial
clinical-stage oncology medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Restoration of Nasdaq compliance follows
On December 18, 2025, the Company received written notification from Nasdaq confirming that Kazia has regained compliance with Nasdaq Listing Rule 5550(b)(1), the
The restoration of full Nasdaq compliance follows the Company's recently announced
"This outcome reflects the progress we have made strengthening the Company's financial position," said Dr. John Friend, M.D., Chief Executive Officer of Kazia. "With full Nasdaq compliance restored and a substantially enhanced balance sheet following our recent financing, we are well-positioned to focus on advancing our clinical programs and building long-term shareholder value."
Kazia believes that the restoration of Nasdaq compliance provides increased clarity for investors and enhances the Company's capital markets flexibility as it continues to advance its clinical-stage oncology pipeline, including ongoing development of paxalisib across brain cancer and advanced breast cancer indications.
For further information contact:
Alex Star
Managing Director
LifeSci Advisors LLC
Astarr@lifesciadvisors.com
Ph: +1 (201) 786-8795
About Kazia Therapeutics Limited
Kazia Therapeutics Limited (NASDAQ: KZIA) is an innovative oncology-focused drug development company, based in Sydney,
Forward Looking Statements
This announcement may contain forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, which can generally be identified as such by the use of words such as "believe," "may," "will," "estimate," "future," "forward," "anticipate," or other similar words. Any statement describing Kazia's future plans, strategies, intentions, expectations, objectives, goals or prospects, and other statements that are not historical facts, are also forward-looking statements, including, but not limited to, statements regarding: the Company's future expectations, plans and prospects, including the benefits of regaining Nasdaq compliance. Such statements are based on Kazia's current expectations and projections about future events and future trends affecting its business and are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements, including risks and uncertainties: related to market and other conditions, associated with clinical and preclinical trials and product development, including the risk that preliminary or interim data may not reflect final results, related to regulatory approvals, and related to the impact of global economic conditions. These and other risks and uncertainties are described more fully in Kazia's most recent Annual Report, filed on form 20-F with the SEC, and in subsequent filings with the SEC. Kazia undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required under applicable law. Investors should not place undue reliance on these forward-looking statements, which apply only as of the date of this announcement.
View original content:https://www.prnewswire.com/news-releases/kazia-therapeutics-regains-full-nasdaq-listing-compliance-302647695.html
SOURCE Kazia Therapeutics Limited